JP2013540771A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540771A5
JP2013540771A5 JP2013533235A JP2013533235A JP2013540771A5 JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5 JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5
Authority
JP
Japan
Prior art keywords
insulin
terminal
pharmaceutical composition
terminally modified
modified insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013533235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/068019 external-priority patent/WO2012049307A2/en
Publication of JP2013540771A publication Critical patent/JP2013540771A/ja
Publication of JP2013540771A5 publication Critical patent/JP2013540771A5/ja
Withdrawn legal-status Critical Current

Links

JP2013533235A 2010-10-15 2011-10-14 新規n末端修飾インスリン誘導体 Withdrawn JP2013540771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10187706.6 2010-10-15
EP10187706 2010-10-15
US39409010P 2010-10-18 2010-10-18
US61/394,090 2010-10-18
PCT/EP2011/068019 WO2012049307A2 (en) 2010-10-15 2011-10-14 Novel n-terminally modified insulin derivatives

Publications (2)

Publication Number Publication Date
JP2013540771A JP2013540771A (ja) 2013-11-07
JP2013540771A5 true JP2013540771A5 (enExample) 2014-11-20

Family

ID=43638785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533235A Withdrawn JP2013540771A (ja) 2010-10-15 2011-10-14 新規n末端修飾インスリン誘導体

Country Status (5)

Country Link
US (1) US20140315797A1 (enExample)
EP (1) EP2627670A2 (enExample)
JP (1) JP2013540771A (enExample)
CN (1) CN103154024A (enExample)
WO (1) WO2012049307A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
PH12017500935A1 (en) * 2014-11-21 2017-11-27 Merck Sharp & Dohme Insulin receptor partial agonists
US20180244743A1 (en) * 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US20190010206A1 (en) * 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
AR106364A1 (es) * 2015-08-25 2018-01-10 Novo Nordisk As Derivados de insulina y sus usos médicos
AU2017267634C1 (en) * 2016-05-16 2022-05-26 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
TW201917134A (zh) 2017-08-17 2019-05-01 丹麥商諾佛 儂迪克股份有限公司 新穎的醯基化胰島素類似物及其用途
WO2020120477A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin analogs having reduced insulin receptor binding affinity
JP7640462B2 (ja) * 2019-03-29 2025-03-05 ノヴォ ノルディスク アー/エス グルコース感受性インスリン誘導体
DK4073097T3 (da) 2019-12-11 2024-08-19 Novo Nordisk As Nye insulinanaloger og anvendelser heraf

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0792290T1 (en) * 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
JP5410020B2 (ja) * 2005-02-02 2014-02-05 ノヴォ ノルディスク アー/エス インスリン誘導体
WO2006125763A1 (en) 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
US20110144010A1 (en) * 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
ES2548304T3 (es) * 2007-08-15 2015-10-15 Novo Nordisk A/S Análogos de la insulina que contienen una fracción acilo y alquilenglicol
WO2009115469A1 (en) * 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
JP5591243B2 (ja) * 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー/エス ペプチド又はタンパク質のアシル化の方法
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010060667A1 (en) * 2008-11-28 2010-06-03 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
EP2523655A2 (en) 2010-01-12 2012-11-21 Novo Nordisk A/S Pharmaceutical compositions for oral administration of insulin peptides

Similar Documents

Publication Publication Date Title
WO2011153493A3 (en) Biodegradable lipids for the delivery of active agents
WO2008137758A3 (en) Amino acid lipids and uses thereof
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
PE20171095A1 (es) Acidos grasos novedosos y su uso en la conjugacion con biomoleculas
EP2810661A3 (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP4410317A3 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2011141705A8 (en) Novel cationic lipids and methods of use thereof
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
NZ602557A (en) Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2014014613A3 (en) Self-assembling peptides, peptide nanostructures and uses thereof
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
WO2015184256A3 (en) Biodegradable lipids for delivery of nucleic acids
EP2871180A4 (en) 2-AMINONICOTINIC ETER DERIVATIVE AND BACTERICIDE THEREFOR AS ACTIVE SUBSTANCE
WO2012054500A3 (en) Compositions for drug administration
WO2008052173A3 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2015048498A3 (en) Carrier-free biologically-active protein nanostructures
EP3760638A3 (en) Compositions and methods utilizing lysophosphatidylcholine scaffolds
EP3037417A3 (en) 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
WO2013096958A8 (en) Compositions and methods for the delivery of biologically active rnas
Muthukumarasamyvel et al. Hierarchical self-assembly of bile-acid-derived dicationic amphiphiles and their toxicity assessment on microbial and mammalian systems
EP2928462A4 (en) METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
RU2015140996A (ru) Топическая противомикробная дерматологическая композиция
WO2010080754A3 (en) Nanoparticle pharmaceutical formulations
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same